Shanton Pharma is a clinical-stage biotech company founded in 2016, with a research focus on the unmet needs associated with gout, hyperuricemia, and pruritus. Our team focuses its resources on these important therapeutic areas through advanced and innovative drug research and developmental approaches.
The Shanton team has researched hyperuricemia and gout for many years, resulting in the development of our lead product, SAP-001 for the treatment of refractory and/or tophaceous gout and the prevention of asymptomatic hyperuricemia developing into gout. SAP-001 has been shown in clinical studies to be safe and effective in patients with symptomatic hyperuricemia and gout. SAP-001 is a convenient oral monotherapy that can bring blood uric acid below 3 mg/dL, and by reducing the dose, maintain uric acid levels between 3-5 mg/dL for a long period of time, dissolving tophi and preventing crystals from forming again.